Literature DB >> 31576309

Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?

Alexander G Raufi1, Khaldoun Almhanna2.   

Abstract

Entities:  

Year:  2019        PMID： 31576309      PMCID： PMC6685860          DOI： 10.21037/atm.2019.04.82

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

3.  Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Authors:  Toshihiro Kudo; Yasuo Hamamoto; Ken Kato; Takashi Ura; Takashi Kojima; Takahiro Tsushima; Shuichi Hironaka; Hiroki Hara; Taroh Satoh; Satoru Iwasa; Kei Muro; Hirofumi Yasui; Keiko Minashi; Kensei Yamaguchi; Atsushi Ohtsu; Yuichiro Doki; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

4.  The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.

Authors:  Emily Z Keung; Esosa U Ukponmwan; Alexandria P Cogdill; Jennifer A Wargo
Journal:  Ann Surg Oncol       Date:  2018-03-02       Impact factor: 5.344

5.  Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

Authors:  Melina Arnold; Mathieu Laversanne; Linda Morris Brown; Susan S Devesa; Freddie Bray
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

6.  Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.

Authors:  D H Ilson; R G Wadleigh; L P Leichman; D P Kelsen
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

7.  Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

Authors:  Toshihiko Doi; Sarina A Piha-Paul; Shadia I Jalal; Sanatan Saraf; Jared Lunceford; Minori Koshiji; Jaafar Bennouna
Journal:  J Clin Oncol       Date:  2017-11-08       Impact factor: 44.544

8.  The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.

Authors:  M J D Prins; J P Ruurda; P J van Diest; R van Hillegersberg; F J W Ten Kate
Journal:  Ann Oncol       Date:  2013-01-18       Impact factor: 32.976

9.  Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

Authors:  Manish A Shah; Takashi Kojima; Daniel Hochhauser; Peter Enzinger; Judith Raimbourg; Antoine Hollebecque; Florian Lordick; Sung-Bae Kim; Masahiro Tajika; Heung Tae Kim; A Craig Lockhart; Hendrik-Tobias Arkenau; Farid El-Hajbi; Mukul Gupta; Per Pfeiffer; Qi Liu; Jared Lunceford; S Peter Kang; Pooja Bhagia; Ken Kato
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

10.  CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

Authors:  Yelena Y Janjigian; Johanna Bendell; Emiliano Calvo; Joseph W Kim; Paolo A Ascierto; Padmanee Sharma; Patrick A Ott; Katriina Peltola; Dirk Jaeger; Jeffry Evans; Filippo de Braud; Ian Chau; Christopher T Harbison; Cecile Dorange; Marina Tschaika; Dung T Le
Journal:  J Clin Oncol       Date:  2018-08-15       Impact factor: 44.544
View more
  3 in total

1.  Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients.

Authors:  Dong Han; Jiajia Zhang; Jingjing Zhao; Tongda Lei; Xi Chen; Tian Zhang; Hui Wei; Yong Guan; Jing Wang; Wencheng Zhang; Lujun Zhao; Jun Wang; Zhiyong Yuan; Yongchun Song; Ningbo Liu; Qingsong Pang; Ping Wang
Journal:  Ann Transl Med       Date:  2020-09

2.  CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.

Authors:  Cao Gao; Yan-Jie Xu; Lei Qi; Ya-Fei Bao; Lei Zhang; Liang Zheng
Journal:  Cell Biol Toxicol       Date:  2021-05-20       Impact factor: 6.819

Review 3.  Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence.

Authors:  Koosha Paydary; Natalie Reizine; Daniel V T Catenacci
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.